Novo Nordisk's Earnings Reckoning: Options Traders Price In a Rare Double-Digit Swing
Published on 08/03/2026 at 16:46 | Redaktion boerse-global.de
For a company that spent the better part of a year selling investors on a diversification story, Novo Nordisk heads into its interim report with that narrative in tatters. The Danish pharmaceutical giant has absorbed two body blows in the span of a week — a failed late-stage trial and a partial legal defeat — and now faces a Wednesday earnings release that options traders believe could produce one of the most violent single-day reactions of the year.
The immediate trigger for the latest slide came on July 31, when Novo disclosed that Ziltivekimab, its experimental cardiovascular drug, had missed its primary endpoint. The ZEUS study, which enrolled more than 6,300 patients with atherosclerosis, chronic kidney disease and elevated inflammatory markers, tested whether the therapy could prevent cardiovascular death, heart attack or stroke versus placebo. The result: a hazard ratio of 0.99, meaning essentially no risk reduction whatsoever.
The Copenhagen-listed shares fell as much as 10 percent on the news, while the US listing dropped 8.6 percent in pre-market trading. Jefferies and Citi analysts both argued the market reaction was overdone, pointing out that Ziltivekimab represented only a small slice of the overall portfolio. But the strategic damage is harder to dismiss. The failure strips away one of Novo's most credible growth avenues outside its obesity franchise, leaving the company even more dependent on execution in the weight-loss segment — and on externally acquired innovation. That undercuts the very diversification pitch management has been making to investors all year.
The second setback carries a longer tail. On July 28, a US federal judge ruled that Novo must face part of a shareholder lawsuit alleging the company misled investors about the tolerability of CagriSema, its next-generation obesity candidate. The 56-page ruling dismissed many of the claims, but enough survived: investors had plausibly shown that the chief scientific officer deliberately misled shareholders about dosing protocols. The case now moves to discovery, which means CagriSema will linger in headlines for months rather than being closed off as a finished chapter.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The stock enters Wednesday's report at roughly 40.90 euros, about 25 percent below its January high of 54.86 euros and nearly flat against its 50-day moving average — a picture of a market that has lost its bearings. The shares are hovering almost exactly on the 200-day average of 40.34 euros, a level that already prices in a considerable amount of disappointment.
Options traders are bracing for outsized movement. According to Saxo Bank calculations, the options market is pricing in an expected swing of roughly 8 percent for the US listing around the earnings date, implying a trading range of approximately $44.90 to $52.60. That estimate covers not just the trading day itself but also several days of drift afterward. Historical precedent suggests a smaller move: following the last two quarterly reports, the stock fell 6.7 percent and 5.4 percent respectively on the following day, per Saxo's Bloomberg data. The market is clearly anticipating something more dramatic this time.
The bar for a positive surprise has been lowered considerably. Analyst consensus for quarterly earnings per share has been cut by roughly 24 percent over the past year to about 5.02 Danish kroner. That reduced hurdle makes an upside beat easier to clear. Yet the analyst community remains deeply split on the company's prospects. Among 26 analysts covering the Copenhagen-listed B-shares, the consensus rating is "hold" with an average price target of 317.20 Danish kroner — but individual targets range from 200 to 453 kroner, a spread that reflects profound disagreement over the outcome of the obesity race against Eli Lilly. The US side looks somewhat more optimistic: a broader panel of 37 analysts shows a 68 percent buy rating with an average 12-month target of $51.19.
Competitive pressure only sharpens the uncertainty. Eli Lilly published positive Phase 3 data for its candidate Retatrutide on July 23, while Novo still commands roughly 89 percent of the US market for oral GLP-1 medications with its Wegovy pill since launching in January. The dynamic shaping Wednesday's analyst questions is straightforward: Novo defends its lead in the oral segment while Lilly closes ground with a potentially stronger injectable. The US listing has risen about 8.7 percent since the first-quarter results, and a raise to the full-year guidance is widely expected — and likely already priced in.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
For investors, the combination of lowered earnings expectations and an anticipated guidance hike suggests the share-price reaction may hinge less on the headline numbers than on management's commentary around US pricing trends and the pace of the international Wegovy pill rollout. A relative strength index of 40 signals neither an oversold extreme nor a convincing bottom — the market has yet to decide whether the Ziltivekimab failure and the CagriSema lawsuit are one-off missteps or symptoms of a deeper execution problem.
With annualized 30-day volatility running at 34.36 percent, sharp moves in either direction around Wednesday's report are probable. The question is whether Novo can demonstrate that pricing discipline in its core US business holds — and whether the oral Wegovy pill's growth story can offset the mounting competitive and legal pressures. Until the company proves that with its own numbers, the current level looks less like a floor and more like a fragile equilibrium.
Ad
Novo Nordisk Stock: New Analysis - 3 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
